In The Know
Short Film Festival

Lights. Camera. Congratulations!

Fertility LifeLines™ and RESOLVE: The National Infertility Association, together with an expert panel of judges, have chosen the In The Know Short Film Competition winner and runners-up! Their films were screened during the In The Know Short Film Festival on November 5. You can watch the three films below.

You will need Adobe Flash Player to view this content.

Important information regarding the films: The views expressed in the film(s) are solely that of the filmmakers and do not necessarily reflect the views or policies of EMD Serono, Inc., or its affiliates. EMD Serono does not guarantee the accuracy of the information presented in the film(s) and is not responsible for any consequences of its use. Any treatments mentioned in the films were specific to each patient. Please talk to your physician if you are experiencing infertility to discuss which treatment options may be available to you.

Click here to learn more about the winner and runners-up.

The In The Know Short Film Competition sought to eliminate the stigma of infertility and encourage couples who have struggled with infertility to share their stories and lend support for other couples hesitant in openly discussing their journey. The Competition’s call for entries was held earlier in the year asking couples to send in a short film narrating their paths to parenthood. The three most compelling films were screened during the November 5 In The Know Short Film Festival where the winner and runners-up were announced.

The live event was moderated by program judge Barbara Collura, Executive Director of RESOLVE. Other judges, including Dr. Robert Stillman, Medical Director of Shady Grove Fertility Reproductive Science Center; Dr. William Hummel, Medical Director of San Diego Fertility Center; and Melissa Ford, Author of Navigating the Land of If and the blog Stirrup Queens, provided their insights on the films.

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

Important Considerations:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Considerations:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading

View the Full Glossary